

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
162/LG/SE/AUG/2019/6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

August 05, 2019

To,
Listing Department,
Bombay Stock Exchange Limited,
PhirozeJeejabhoy Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 509079

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

SYMBOL: GUFICBIO

Dear Sir/Madam,


Sub: Intimation of Appointment of Mr. Satyen Manikani as a Senior Vice President - Strategy and Business Development of the Company

In order to sharpen the vision and ensure precise execution of the strategy adopted by the Company, the Company have recently appointed Mr. Satyen Manikani as a Senior Vice President - Strategy and Business Development of the Company. His brief profile is enclosed herewith, for your reference.

You are requested to take the same on record.

Yours faithfully,

For Gufic Biosciences Limited



Ami N. Shah
Company Secretary & Compliance Officer
Membership No. A39579



Encl: as above

Brief Profile :

Mr. Satyen (Aged 48 years) is a B. Pharmacy graduate with Masters in Business Management and Strategic Planning. He has rich experience of over 24 years in Pharmaceutical Marketing, Sales, Strategic Marketing, Licensing and Sales Force Effectiveness.

Mr. Satyen has experience in wide range of therapy areas like Antinfectives, Gastroenterology, Nutraceuticals, Dermatology, Pain Management, Arthritis, Gynaecology, Oncology, Cardiology, Neurology, Diabetology, Urology ,Wound care management ,Critical care Biologicals and Dermo-Cosmetics

He has been associated with many well-known pharma companies such as Ranbaxy Laboratories Limited (Now acquired by Sun Pharma Industries Limited), Sun Pharma Industries Limited, Piramal Enterprises Limited etc. He was last associated with Alkem Laboratories Limited as a Vice President-Strategy and Business Development since October 2010.

His role in the Company inter alia will be (i) defining the overall corporate strategy for the company to meet the predefined goals set by the core management committee, (ii) evaluating the domestic and global market opportunities and finding the avenues for growth in line with the corporate objectives, (iii) defining the overall new product strategy for the company in collaboration with the Business heads, (iv) identifying therapy gaps and thereby recommending new products; (v) Identifying and build a new product pipeline (small molecules and Biologicals) for the company by working in coordination with Business heads, Medical, Regulatory and the IP team; (vi) Identifying opportunities for acquisition and hive off products/division to enhance focus on core strength and other planning related task.

